Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Study of Docetaxel in Breast Cancer Patients
- Conditions
- Breast Neoplasms
- Interventions
- Drug: epidoxorubicine, ciclophosphamide, methotrexate, fluorouracileDrug: epidoxorubicine, docetaxel, ciclophosphamide, methotrexate, fluorouracile
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2009-12-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 998
- Registration Number
- NCT00174707
- Locations
- 🇮🇹
Sanofi-Aventis Administrative Office, Milan, Italy
CHOOSE : Telithromycin, Acute Bacterial Sinusitis
- Conditions
- Sinusitis
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2009-09-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 298
- Registration Number
- NCT00174694
Insulin Glulisine in Diabetes Mellitus, Type 2
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2009-09-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 311
- Registration Number
- NCT00174668
- Locations
- 🇷🇴
Sanofi-aventis, Bucharest, Romania
🇬🇧Sanofi-Aventis, Guildford, United Kingdom
Opposing Step-by-step Insulin Reinforcement to Intensified Strategy
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2009-09-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 811
- Registration Number
- NCT00174642
- Locations
- 🇬🇧
Sanofi-Aventis, Guildford, United Kingdom
CASPAR : Clopidogrel and Acetyl Salicylic Acid in Bypass Surgery for Peripheral ARterial Disease
- Conditions
- Arterial Occlusive Diseases
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1460
- Registration Number
- NCT00174759
- Locations
- 🇬🇧
Sanofi-Aventis, Guildford, United Kingdom
CORE: Capecitabine, Oxaliplatin, Radiotherapy and Excision
- Conditions
- Rectal Neoplasms
- Interventions
- Drug: Oxaliplatin, capecitabine, radiotherapy
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2009-12-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 87
- Registration Number
- NCT00174616
- Locations
- 🇬🇧
Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom
Study Comparing Radiochemotherapy With Folfox 4 Regimen or 5FU-Cisplatin in Patients With Inoperable Esophageal Cancer
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2009-12-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 97
- Registration Number
- NCT00160030
- Locations
- 🇫🇷
Sanofi-Aventis, Paris, France
Insulin Glargine Plus Insulin Glulisine Multiple Daily Injections (MDI) Versus Premix Insulin Treatment in Subjects With Diabetes Mellitus (Type 1 or Type 2)
- Conditions
- Diabetes Mellitus
- Interventions
- First Posted Date
- 2005-08-26
- Last Posted Date
- 2009-06-04
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 582
- Registration Number
- NCT00135941
- Locations
- 🇺🇸
Advanced Healthcare, Milwaukee, Wisconsin, United States
Insulin Glulisine Administered Pre-meal Versus Post-meal in Adult Subjects With Type 2 Diabetes Mellitus Receiving Insulin Glargine as Basal Insulin
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2005-08-25
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 345
- Registration Number
- NCT00135096
- Locations
- 🇺🇸
Sanofi-aventis, Bridgewater, New Jersey, United States
Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis
- Conditions
- Multiple Sclerosis
- Interventions
- Drug: Placebo (for teriflunomide)
- First Posted Date
- 2005-08-25
- Last Posted Date
- 2013-01-04
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1088
- Registration Number
- NCT00134563
- Locations
- 🇨🇦
sanofi-aventis, Canada, Laval, Canada
🇸🇪Sanofi-Aventis, Bromma, Sweden
🇩🇪Sanofi-Aventis Deutschland GmbH, Berlin, Germany